The Role of Vitamin D in Corneal Epithelial Barrier Function, Ocular Microbiome, Ocular Inflammation, and Visual Acuity of Children With Allergic Conjunctivitis
Launched by CHINA MEDICAL UNIVERSITY HOSPITAL · Apr 21, 2023
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The prevalence of allergic conjunctivitis (AC) has rapidly increased in recent decades, resulting in a significant global public health concern. The ocular surface is a unique mucosal immune compartment in which immunological features act in concert to foster a tolerant microenvironment (immune privilege). The corneal epithelial barrier is the first line of defense that forms a protective barrier against pathogens, pollutants, and allergens. The ocular microbiota has a role in maintaining the homeostasis of the ocular surface and preservation of barrier function. Vitamin D functions as enfo...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Children aged 6-18 years with allergic conjunctivitis (AC) diagnosed by ophthalmologists or allergists
- Exclusion Criteria:
- • 1. Previous eye surgery
- • 2. Active eye infection
- • 3. Any active inflammatory eye disease except AC
- • 4. Systemic steroid use within 28 days of study
About China Medical University Hospital
China Medical University Hospital is a leading healthcare institution dedicated to advancing medical research and enhancing patient care through innovative clinical trials. Affiliated with China Medical University, the hospital is renowned for its comprehensive approach to medical education and research, fostering collaboration between healthcare professionals and academic experts. With state-of-the-art facilities and a commitment to ethical standards, the hospital conducts rigorous clinical trials aimed at improving treatment outcomes across various medical disciplines, contributing significantly to both local and global healthcare advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Taichung, , Taiwan
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported